Teva Gains Favorable Ruling on Copaxone from European Patent OfficeBy
Teva Pharmaceutical Industries Ltd. reports that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan, and an unidentified third party concerning Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).
On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for Copaxone, expiring September 9, 2025. The European Patent Office specifically determined that claims 1-12 of the ‘528 patent are valid. Therefore infringing follow-on glatiramer products would not be able to launch prior to patent expiry, according to Teva
Source: Teva Pharmaceutical Industries